摘要
[目的]评价PTEN表达水平与转移性结直肠癌(mCRC)患者西妥昔单抗临床获益之间的关系,为临床用药和个性化治疗提供参考。[方法]计算机检索PubMed、CNKI、CBM和万方中文数据库,采用Meta分析的方法,评价PETN表达与mCRC患者西妥昔单抗疗效的关系。[结果]共纳入文献14篇,病人总人数1 227人。未经K-ras基因筛选mCRC患者PTEN表达阳性与西妥昔单抗治疗敏感性及无进展生存(PFS)均相关。K-ras野生型mCRC患者PTEN表达阳性与西妥昔单抗治疗PFS、总生存(OS)获益有关。[结论]PTEN表达水平可以作为mCRC患者西妥昔单抗临床获益的预测因素。
[Purpose] To evaluate the association between PTEN expression and the clinical benefit of cetuximab therapy for metastatic colorectal cancer（mCRC） patients. [Methods] Literatures were retrieved in PubMed,CNKI,CBM and Wanfang Data. A Metaanalysis was used to analyze the association between expression of PTEN and cetuximab effects in mCRC patients.[Results] A total of 14 retrospective studies and 1 227 cases were included in the Meta-analysis. The results showed that positive PTEN expression was correlated to sensitivity of cetuximab and progression-free survival（PFS） in mCRC patients unselected of K-ras gene. In patients with wild-type K-ras,positive PTEN predicted longer PFS and overall survival（OS）. [Conclusion] PTEN expression is a predictive factor for clinical benefit in mCRC patients treated with cetuximab.
出处
《肿瘤学杂志》
CAS
2013年第11期846-853,共8页
Journal of Chinese Oncology
